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Abstract: Infection with Hepatitis C Virus (HCV) continues to be a major global health 
problem. To overcome the limitations of current therapies using interferon- in combination 
with ribavirin, there is a need to develop drugs that specifically block viral proteins. Highly 
efficient protease and polymerase inhibitors are currently undergoing clinical testing and 
will become available in the next few years. However, with resistance mutations emerging 
quickly, additional enzymatic activities or functions of HCV have to be targeted by novel 
compounds. One candidate molecule is the nonstructural protein 2 (NS2), which contains a 
proteolytic activity that is essential for viral RNA replication. In addition, NS2 is crucial for 
the assembly of progeny virions and modulates various cellular processes that interfere with 
viral replication. This review describes the functions of NS2 in the life cycle of HCV and 
highlights potential antiviral strategies involving NS2. 
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1. Introduction 
About 3% of the world’s population are infected with Hepatitis C Virus (HCV). The existing 
treatment using PEGylated interferon- in combination with ribavirin is efficient in only 55-60% of 
individuals infected with genotype 1 virus, and 80% of genotype 2 or 3 patients [1]. Moreover, the 
therapy is accompanied by serious side effects. This emphasizes the urgent need for specific antiviral 
drugs directed against key functions in the viral life cycle. Several compounds targeting HCV proteins 
or cellular functions involved in HCV replication are currently being tested clinically and will become 
available in the next few years (reviewed in [2]). However, mutant viruses that are resistant against 
these drugs have emerged in vitro and in vivo, suggesting that several enzymatic activities or other 
viral functions may have to be targeted in parallel in a combinatory approach, similar to the highly 
active antiretroviral therapy (HAART) against Human Immunodeficiency Virus (HIV) [3]. 
The positive-strand RNA genome of HCV contains a single open reading frame encoding a   
3,011-amino acid polyprotein precursor, which is co- and posttranslationally cleaved into individual 
proteins (Figure 1) [4]. The amino-terminus contains the structural proteins (core, envelope proteins E1 
and E2), followed by a p7, a small transmembrane protein that assembles into a hexameric ion channel. 
The nonstructural (NS) proteins (NS2, NS3, NS4A, NS4B, NS5A and NS5B) reside in the carboxy-
terminal two thirds of the polyprotein. 
Processing into distinct proteins occurs by action of both host cellular and viral proteases (Figure 1). 
The signal peptidase (SPase) of the host cell cleaves at the junctions between core, E1, E2, p7 and 
NS2. In addition, cellular signal peptide peptidase (SPPase) liberates the core from its carboxy-
terminal membrane anchor. Processing of the nonstructural region of the HCV polyprotein is mediated 
by two virus-encoded proteases: the NS3/4A protease, which cleaves all NS proteins downstream of 
NS3, whereas the NS2-3 protease mediates a single cleavage at the junction between NS2 and NS3. 
Figure 1. Processing of the HCV Polyprotein. The 3,011-amino acid polyprotein 
contains 10 HCV proteins, with the structural proteins (core, E1, E2) in the N-terminal 
third, and p7 and the nonstructural proteins (NS2, NS3, NS4A, NS4B, NS5A and NS5B) in 
the C-terminal two thirds. Cleavage of the polyprotein in the structural region and p7 
occurs by action of the host cell signal peptidase (black circles) and the signal peptide 
peptidase (black diamond), whereas processing in the nonstructural region is mediated by 
the NS2-3 protease (open arrowhead) and the NS3/4A protease (closed arrowhead). The 
NS2-3 protease is shown as a dotted-line box. N, amino-terminus; C, carboxy-terminus. 
 
 
The NS3/4A protease was characterized extensively by biochemical and biophysical methods, and 
structural information became available within a few years after the viral genome was isolated [5-10]. 
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HCV. Two compounds targeting the NS3/4A protease, telaprevir and boceprevir, are expected to reach 
the market in the next few years [11-12]. This will be a significant improvement over the current 
treatment with PEGylated interferon- in combination with ribavirin. 
In contrast to NS3/4A, NS2 and the NS2-3 protease were studied by a few groups only, mainly due 
to the hydrophobic nature of NS2. However, significant progress has been made recently with the 
solution of the crystal structure of the NS2 protease domain, as well as the elucidation of multiple 
additional functions, many of which are crucial for maintaining important steps in the viral life cycle. 
With the help of these findings, NS2 has become an attractive candidate molecule for the development 
of antiviral drugs. 
2. The NS2-3 Protease 
NS2 (217 amino acids, molecular weight 23 kDa) is a nonstructural protein with a hydrophobic 
amino-terminal subdomain containing up to three putative transmembrane segments and a carboxy-
terminal cytoplasmic domain. NS2 from the H77 strain (genotype 1a) is rapidly degraded in cells by 
the proteasome, whereas JFH1 NS2 (genotype 2a) is more stable [13-15]. These results indicate that 
the expression of NS2 is tightly regulated, and that protein turnover may vary between different HCV 
genotypes.  
The C-terminal domain (residues 94-217) of NS2, together with residues 1-181 of NS3, forms the 
NS2-3 protease [16-21]. Cleavage at the NS2/NS3 junction is required for RNA replication of full-
length HCV replicons [22], in the infectious tissue culture system [23], and in chimpanzees [24]. It is 
possible that not NS2 itself, but a free N-terminus of NS3 is necessary for the onset of replication. 
Whether NS2 has a direct role in the replication of HCV genomes remains to be determined. 
Based on sequence alignments and mutagenesis experiments, a putative catalytic triad was 
identified shortly after the NS2-3 protease was discovered [16-17]: His 143, Glu 163 and Cys 184 are 
entirely conserved in all HCV isolates, and mutagenesis of any of these residues to alanine abrogates 
proteolytic activity. NS2-3 cleavage efficiency was increased by the addition of exogenous zinc and 
inhibited by metal chelators, indicating that NS2-3 might be a metalloprotease [17]. However, the 
dependence on zinc may be attributed to the NS3 portion of the NS2-3 protease, since the crystal 
structure of the NS3 protease domain contained a tightly coordinated zinc ion stabilizing the protein 
[8-9]. Limiting zinc may affect the folding of the NS3 protease domain, which in turn could interfere 
with NS2-3 processing [25]. 
  The composition of the catalytic triad and comparison with other viral proteases led to the 
alternative hypothesis that NS2-3 was a cysteine protease [26]. This idea was further supported by the 
finding that classical cysteine protease inhibitors, such as N-ethylmaleimide or iodoacetamide, blocked 
NS2-3 cleavage [19-20]. 
The precise role of the NS3 protease domain in the processing of NS2-3 remains to be elucidated. 
Schregel et al. have shown that NS2 is a bona fide protease that shows basal activity with as little as 
two residues of NS3, although the presence of the entire protease domain (residues 1-181) significantly 
increased the cleavage efficiency [27]. They also ruled out a catalytic role for the zinc ion of NS3 in 
NS2-3 processing, supporting the classification of NS2-3 as a cysteine protease. It is possible that the Viruses 2010, 2                                       
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NS3 protease domain aids the proper folding of NS2 by correctly placing the scissile bond at the 
NS2/NS3 junction in the active site. 
Crystal Structure of the NS2 Protease Domain 
Confirmation that NS2-3 was a cysteine protease came with the solution of the crystal structure of 
the NS2 portion of the NS2-3 protease (Figure 2a) [28]. NS2
pro (residues 94-217) showed a novel 
overall fold with no known cellular or viral structural homologues. One solvent-exposed face of the 
structure was hydrophobic, which has led to the hypothesis that the protease domain may be 
peripherally inserted into a cellular membrane. The crystal structure showed that NS2
pro formed 
dimers, with extensive contacts between the two molecules and a domain exchange of the carboxy-
terminal subdomains. 
His 143, Glu 163 and Cys 184, which were identified earlier as putative active site residues, formed 
a catalytic triad that could be superimposed with other viral cysteine proteases, thus firmly establishing 
the classification of NS2 as a cysteine protease (Figure 2b). Interestingly, the NS2
pro dimer contained a 
pair of composite active sites, with His 143 and Glu 163 contributed by one monomer, whereas Cys 
184 originated from the other monomer. This implied that dimerization of NS2 was required for 
processing at the NS2/NS3 junction. It was suggested previously that the NS2-3 cleavage reaction 
might be bimolecular [19,29], and the dimeric enzymatic mechanism proposed based on the crystal 
structure of NS2
pro was confirmed by a series of experiments in mammalian cells [28]. 
Figure 2. Crystal Structure of the NS2 Protease Domain (NS2
pro). (a) NS2
pro forms a 
dimer with an N-terminal alpha-helical  subdomain and a domain-swapped C-terminal 
antiparallel beta sheet. The two dashed boxes indicate the active sites, with the catalytic 
triad represented in green. (b) Detailed view of the NS2
pro active site. His 143 and Glu 163 
originate from one monomer, and the nucleophilic Cys 184 is provided by the other 
monomer. The C-terminal Leu 217 remains bound in the active site. Pro 164, which lies 
immediately downstream of the catalytic Glu residue, is in a cis-peptide conformation. N, 
amino-terminus;  C, carboxy-terminus. This figure was generated using PyMOL 
(http://www.pymol.org).  
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The unusual arrangement of the NS2
pro active site offers interesting regulating possibilities. The 
finding that NS2 dimerization is required for proteolysis suggests that certain concentrations of the 
protein have to be accumulated before NS2-3 processing and thus initiation of RNA replication can 
occur. A delayed enzyme kinetic may allow the virus to generate sufficient amounts of NS3/4A to 
antagonize the activation of the interferon pathway before the onset of viral replication [30]. 
The crystal structure also showed that the backbone of the carboxy-terminal residue of NS2, Leu 
217, remained bound in the active site, making contact to the residues of the catalytic triad. This 
suggests that Leu 217 may prevent other substrates from accessing the active site of NS2
pro, locking 
the enzyme in an inactive conformation. This may represent an additional mechanism of the virus to 
tightly regulate processing of NS2-3. 
Pro 164, which follows immediately downstream of the catalytic residue Glu 163, showed a cis-
conformation in the crystal structure. The cis-peptide configuration of Pro 164 may be required to 
establish the correct geometry at the active site of NS2
pro, or for the molecule to form dimers. The 
presence of a cis-proline implies that a cellular enzyme, a prolyl-peptidyl cis-trans isomerase, is 
required to mediate proper folding of NS2. 
3. Role of NS2 in Virus Assembly 
For many years, the protease activity was the only function known for NS2. In recent years, NS2 
was shown to be involved in a variety of other processes during the viral life cycle, including a crucial 
function in virus assembly. Using deletion mutants in bicistronic HCV RNAs containing an internal 
ribosomal entry site (IRES) from encephalomyocarditis virus (EMCV) between NS2 and NS3, several 
groups showed that full-length NS2 was required for production of virus particles [23,31]. Mutating 
residues of the catalytic triad to alanine did not impair virus production, indicating that the NS2 
protease activity itself was not required to generate progeny virions.  
The N-terminal transmembrane segment of NS2 seems to play an important role in HCV particle 
production. Experiments with chimeric HCV derived from two different genotypes or two strains of 
the same genotype showed that virus production was most efficient when the transition point between 
the two genomes was placed after the first transmembrane segment of NS2 [32]. These results indicate 
that the N-terminus of NS2 may interact with upstream structural proteins via its first transmembrane 
segment, whereas the C-terminal part of NS2, including the protease domain, binds to downstream 
nonstructural proteins. 
The structure of the first transmembrane segment of NS2 was solved by solid-state NMR, showing 
a flexible helix in the N-terminal part (residues 3-11) connected to a stable alpha helix (residues 12-21) 
via two glycine residues [31]. The amino acid residues on one face of the helix are highly conserved 
within the same HCV genotype, and mutagenesis of residues in this region significantly reduces virus 
production. Gly 10, a residue that is entirely conserved amongst all HCV isolates, may act as a “hinge” 
to enable intramembrane protein-protein interactions. 
Yi et al. described a role for NS2 at a late stage of virus assembly, subsequent to the involvement of 
core, NS3 and NS5A [15]. In addition, they showed by confocal microscopy experiments that NS2 co-
localized with several other HCV proteins, especially E2 and NS5A, indicating that NS2 may directly 
or indirectly interact with various other HCV structural and nonstructural proteins. The authors Viruses 2010, 2                                       
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suggested that similar to NS2A in the flaviviruses [33], HCV NS2 may induce membrane alterations 
and envelope protein rearrangements to facilitate virus assembly and release. 
These findings demonstrate that multiple regions of NS2, including the N-terminal transmembrane 
segment and the cytoplasmic protease domain, are essential for virus production. NS2 may act as a 
“bridging factor” to bring core, E1/E2 and the viral RNA, which is synthesized by the replication 
complexes composed of nonstructural proteins, into close proximity for incorporation into virions. The 
detailed molecular mechanisms of these processes remain to be elucidated in future studies. 
4. Cellular Proteins Interacting with NS2 
Various interactions between NS2 and cellular proteins have been reported. NS2 was suggested to 
interfere with apoptosis [34], inhibit cell proliferation by inducing cell cycle arrest [35], and to regulate 
cAMP-dependent pathways [36], cytokine expression [37] and liver fat metabolism [38]. Moreover, 
NS2 is a target for phosphorylation by casein kinase 2 (CK2) and subsequent degradation [13]. Since 
most of these experiments were carried out in mammalian tissue culture systems using overexpressed 
NS2, the in vivo relevance of some these functions remains to be determined. 
In addition, cellular proteins that regulate the synthesis and folding of NS2 were described. The 
ATP-hydrolyzing activity of the molecular chaperone Hsp90 was shown to be necessary for NS2-3 
cleavage in cell-free assays and in tissue culture experiments [39]. The chaperone may be required for 
the proper folding of NS2, or for the correct spatial arrangement of the NS2 and NS3 domains to allow 
cleavage of the scissile bond. 
Cyclosporine A has been reported to decrease the replication levels of HCV genomes in vitro and in 
vivo by many groups (reviewed in [40]). Recently, it was revealed that NS2 was one of the enzymes 
targeted by cyclosporine A [41]. The inhibitory effect is mediated by the host cellular peptidyl-prolyl 
cis-trans isomerase Cyclophilin A. The most likely target proline in NS2 is Pro 164, which is highly 
conserved in all HCV genotypes. Cyclophilin A would promote isomerization of Pro 164 from a trans- 
to a cis-conformation, allowing proper folding of the enzyme and establishing the correct geometry at 
the active site for NS2-3 cleavage to occur (Figure 2b). 
5. Potential Antiviral Therapies Targeting NS2 
In the past few years, significant progress has been made on the biochemical and biophysical 
characterization of HCV NS2, and multiple roles of the protein in the viral life cycle have been 
described. The proteolytic activity of NS2-3 is required for the onset of RNA replication, and the 
protein has additional important roles in virus assembly as well as in the modulation of the host cell 
response to viral infection. These studies demonstrate that NS2 is a key enzyme for many functions 
that are essential for the viral life cycle, making it an attractive target for antiviral therapies. The 
following sections describe possible intervention strategies that involve NS2 to limit HCV replication 
and spread. Viruses 2010, 2                                       
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5.1. Protease Active Site 
Inhibiting the enzymatic activity of a viral protease is an effective way to interfere with replication 
of the virus, as demonstrated for the new HCV NS3/4A inhibitors (see above), as well as for the HIV 
protease inhibitors, which are an integral component of HAART (reviewed in [42]). For many years, 
the HCV NS2-3 protease was not considered a good target for antivirals because cleavage at the 
NS2/NS3 junction was thought to be a unimolecular reaction in cis. Autoproteolytic processing at the 
C-terminus of NS2 would imply that processing kinetics may be too fast for inhibition by a drug. The 
finding that NS2-3 is a dimeric enzyme with two active sites that are each composed of residues from 
both monomers significantly prolongs the ‘window of opportunity’ to block proteolysis with small 
compounds. 
Although the crystal structure of NS2
pro represents the post-cleavage form of the NS2-3 protease, 
the spatial arrangement of the catalytic triad of NS2 is similar to other viral cysteine proteases. 
However, the protease inhibitor profile of NS2-3 was ambiguous, since certain classic cysteine 
protease inhibitors, such as E-64, had no effect on NS2-3 processing [20]. On the other hand, serine 
protease inhibitors, including tosyl phenyl chloromethyl ketone (TPCK) and tosyl L-lysine 
chloromethyl ketone (TLCK), inhibited NS2-3 cleavage [19-20]. This finding may be explained by the 
fact that NS2 has an active site geometry that is similar to serine proteases, analogous to cysteine 
proteases from other virus families, e.g. the picornaviral 3C proteases [43]. This unusual feature may 
help in designing and modeling small compounds that specifically target the active site of NS2. 
In addition to small molecule inhibitors, NS2-3 processing can be inhibited by peptides derived 
from NS4A [20,44]. NS4A binds to the N-terminus of NS3 and acts as a cofactor for the NS3 protease. 
NS4A peptides thus probably interfere with proper placement of the scissile bond at the junction 
between NS2 and NS3 in the protease active site. Consistent with the finding that the   
C-terminal Leu 217 remains bound in the active site of NS2
pro, peptides derived from the C-terminus 
of NS2 also inhibited NS2-3 proteolysis, although to a lesser extent [20]. Therefore, peptides derived 
from various regions of the HCV polyprotein may be used to prevent NS2-3 cleavage. 
5.2. NS2 Dimerization 
Experiments with transfected NS2-3 or full-length HCV genomes in mammalian cells suggested 
that dimerization of NS2-3 was required for proteolytic activity and therefore initiation of replication 
[28]. Moreover, dimerization of NS2 is also important for another function aside from proteolysis, as 
shown by the analysis of NS2 mutants in the context of bicistronic HCV genomes with an EMCV 
IRES inserted between NS2 and NS3 [45]. While replication was unaltered, virus production was 
significantly lower for certain mutations at the dimer interface of NS2, whereas amino acid changes at 
the protease active site had no effect. Although it cannot be ruled out completely that these mutations 
affect the folding process of the molecule, these findings suggest that dimerization is crucial for 
multiple functions of NS2. 
In the crystal structure of NS2
pro, the total buried surface area between the two subunits of a dimer 
is 1300 Å
2, and most residues that make contact between the two molecules are highly conserved [28]. 
Based on the crystal structure, small compounds or peptides that prevent NS2 dimerization could be Viruses 2010, 2                                       
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designed and modeled in silico by focusing on areas of an NS2 molecule that are involved in 
contacting the other monomer.  
Targeting the dimerization interface of a protein to interfere with its function(s) is an emerging 
concept to develop therapeutic drugs [46]. It was successfully applied for multiple HIV enzymes, 
including the protease, the integrase, and the two subunits of the HIV reverse transcriptase (reviewed 
in [47]). A similar strategy was suggested for inhibiting chemokine receptors, many of which require 
dimerization to trigger intracellular signaling cascades [48]. 
5.3. Functions of NS2 Involved in Virus Assembly 
Recent findings from experiments with the infectious HCV cell culture system clearly suggest that 
NS2 plays an important role in virus assembly. Therefore, the regions of NS2 that participate in the 
generation and release of viral particles can be targeted by antiviral drugs. Several residues in the NS2 
protease domain that did not affect RNA replication, but impaired release of infectious virus, were 
identified [14-15,45]. However, the precise role of these residues in the assembly process, and their 
interactions with other viral and cellular factors involved in virus particle production, may have to be 
determined before compounds that specifically interfere with virus assembly can be developed. 
5.4. Interactions between NS2 and other Viral Proteins 
Biochemical experiments [49-50] as well as forward genetic selection in cell culture adaptation 
experiments after mutational analysis [15,51-53] have shown that NS2 is involved in a complex 
network of interactions with other viral proteins. Although the precise sites of interaction between NS2 
and other proteins has not been mapped, and some of the interactions may be indirect, inhibitors could 
target the interaction of NS2 with other viral proteins, especially NS3. This strategy may include the 
design of compounds that bind to the surface of NS2 in conserved regions, which are likely to be 
involved in interactions between NS2 and other viral (or cellular) proteins.  
5.5. Cellular Proteins Interacting with NS2 
Aside from targeting NS2 directly, antiviral therapies could also be directed at cellular proteins 
interacting with NS2. Inhibiting host cell factors has a significant advantage over blocking viral 
enzymes, since host cell functions are much less likely to develop resistance mutations. On the other 
hand, a cellular enzyme probably has crucial functions in the host organism. Therefore, the antiviral 
therapy may have detrimental side effects unless there is a redundant mechanism for that cellular 
function. However, one drug targeting a cellular enzyme might be effective against multiple viruses, 
which often rely on the same host cell functions for their replication. 
Various drugs that target cellular functions have been implied in inhibiting HCV replication. As 
mentioned above, cyclosporine A was shown to decrease the proteolytic activity of NS2 by blocking 
the cellular peptidyl-prolyl cis-trans isomerase Cyclophilin A [41]. Several compounds derived from 
cyclosporine A have shown promising results in treating HCV infection in clinical trials. Screening for 
compounds that target other host cell factors interacting with NS2, e.g. the Hsp90 heat shock 
chaperone or casein kinase 2, may lead to the identification of additional inhibitors of HCV replication. Viruses 2010, 2                                       
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6. Conclusions 
With almost half of the individuals infected with genotype 1 HCV not responding to the current 
treatment with interferon- and ribavirin, novel highly efficient therapies are sorely needed. A new 
generation of HCV-specific compounds, most of which target either the NS3 protease or the NS5B 
RNA-dependent RNA polymerase, is expected to become available soon. However, viral escape 
mutants that lead to resistance against these drugs have already emerged. For an efficient and 
sustainable therapy against HCV infection, a strategy targeting multiple enzymatic activities or other 
functions of the viral proteins has the best chance for success. Recent advances in elucidating the 
structure and function of NS2 emphasized on the crucial role of this protein in the HCV life cycle. 
Therefore, NS2 is an excellent candidate molecule to develop additional antiviral therapies against 
HCV infection. 
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